挪威基金削减了对Alnylam的投资, Alnylam是一家生物制药公司,刚刚升级为“购买”。 Norwegian fund cuts investment in Alnylam, a biopharmaceutical stock just upgraded to "buy."

挪威投资者Tredje APfonen将其在Alnylam制药厂的股份削减了一半,而Atria投资公司则增加了股份。 A Norwegian investor, Tredje AP fonden, cut its holdings in Alnylam Pharmaceuticals by half, while Atria Investments Inc. increased its stake. Alnylam是一家发展RNA干扰治疗的生物制药公司,最近将其库存升级为“买”评级,目标价格为304.26美元。 Alnylam, a biopharmaceutical company developing RNA interference-based therapeutics, recently had its stock upgrade to a "buy" rating with a target price of $304.26. 尽管该公司报告了损失,但其市场上限为31.3亿美元。 Despite reporting a loss, the company's market cap is $31.30 billion.